Thursday, June 08, 2017 6:13:44 AM
The market liked when 3 patients were enrolled at the .35 dose. So now that we have surpassed the success of the 1990's trials lets see how the market likes 6 more going in to get the buisness at the listed theraputic dose.
THINK THAT MIGHT CHURN A FEW MORE WARRENTS? AND EXTENED OUR FUNDING BY MORE MONTHS. WELL WE KNOW IT SURE DID WITH OUR FIRST THREE PATIENTS.
http://ww4.fscwire.com/sites/default/files/news_release_pdf/Theralase05262017.pdf
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM